## VANTA BIOSCIENCE LIMITED Secunderabad

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

### FIRST ANNUAL REPORT

2016-2017

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

Registered Office

No.02/G/308/G.No.3/FF/SF 1-20-248, Umajay Complex, 2nd floor, Rasoolpura, SECUNDERABAD - 500 003.

Plant (Research Centre)

Plot No. K2-B, 11<sup>th</sup> Cross Street SIPCOT, Industrial Complex, Gummidipoondi, Tamilnadu – 601201.

**Board of Directors** 

**Sri M. Dopesh Raja** Managing Director

**Sri M. Mohan Krishna** Director

**Dr. Vyasmurti Madhavarao Shingatgeri** - Director

**Dr. Padmanabhuni Venkata Appaji** Director

**Dr. Jang Bahadur Gupta**Director

**Dr. Gonuguntla Kathyayani** Director

**Auditors** 

K B S & ASSOCIATES Chartered Accountants No.403, IIIrd Floor, Padmaja Chambers, Khairatabad, HYDERABAD – 500 004.

Bankers

State Bank of India, SME Branch, Saifabad, Hyderabad.



### Vanta Bioscience Limited

**Regd. Office :** 1-20-248, Umajay Complex, Rasoolpura, Secunderabad - 500 003, INDIA.

Tel : +91 40 6657 5454, 2790 3226

Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

NOTICE

NOTICE IS HEREBY GIVEN THAT THE FIRST ANNUAL GENERAL MEETING OF THE MEMBERS OF VANTA BIOSCIENCE LIMITED WILL BE HELD ON WEDNESDAY, MAY 31, 2017 AT 11.30 A.M. AT THE REGISTERED OFFICE OF THE COMPANY AT NO.02/G/308/G, NO.3/FF/SF/1-20-248, UMAJAY COMPLEX, RASOOLPURA, SECUNDERABAD - 500003, T.S.

### **Ordinary Business**

- 1. To receive, consider and adopt the Financial Statements as at  $31^{st}$  March, 2017 along with the Reports of the Auditors and Directors thereon.
- 2. To appoint a Director in place of Mr. Mohan Krishna Mulakala (DIN: 01448535), who retires by rotation and being eligible, offers himself for re-appointment.
- 3. To appoint Auditors and to fix their remuneration and in this regard, to consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 139 and other applicable provisions of the Companies Act, 2013 read with rules made thereunder, M/s. K B S & Associates, Chartered Accountants (FRN: 011208S) be and are hereby appointed as the statutory auditors of the Company for a term of 5 years from the conclusion of this annual general meeting till the conclusion of the sixth annual general meeting subject to ratification by members each year and that the Board of Directors be and are hereby authorized to fix the remuneration payable to them for the financial year ending March 31, 2018, in addition to reimbursement of all out of pocket expenses in connection with the audit of the accounts of the Company."

### **Special Business**

4. To consider and, if thought fit, to pass, with or without modifications, the following resolution as an ordinary resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013, and the rules made there under, read with Schedule IV to the Companies Act, 2013, Dr. Padmanabhuni Venkata Appaji (DIN 02614167), in respect of whom the Company has received a notice in writing from a member under Section 160 of the Companies Act, 2013 proposing his candidature, be and is hereby appointed as Director of the Company under independent category, to hold office for a period of 5 (five) consecutive years i.e. upto March 19, 2022 and that he shall not be liable to retire by rotation."

Research Center:

K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex, Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.

Tel: 044 6790 1600



5. To consider and, if thought fit, to pass, with or without modifications, the following resolution as an ordinary resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013, and the rules made there under, read with Schedule IV to the Companies Act, 2013, Dr. Jang Bahadur Gupta (DIN 07751205), in respect of whom the Company has received a notice in writing from a member under Section 160 of the Companies Act, 2013 proposing his candidature, be and is hereby appointed as Director of the Company under independent category, to hold office for a period of 5 (five) consecutive years i.e. upto March 19, 2022 and that he shall not be liable to retire by rotation."

6. To consider and, if thought fit, to pass, with or without modifications, the following resolution as an ordinary resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013, and the rules made there under, read with Schedule IV to the Companies Act, 2013, Dr. Gonuguntla Kathyayani in respect of whom the Company has received a notice in writing from a member under Section 160 of the Companies Act, 2013 proposing her candidature, be and is hereby appointed as Director of the Company under independent category, to hold office for a period of 5 (five) consecutive years i.e. upto May 18, 2022 and that he shall not be liable to retire by rotation."

By order of the Board for VANTA BIOSCIENCE LIMITED

M. Dopal Kajo

MULAKALA DOPESH RAJA

Managing Director DIN: 01176660

May 09, 2017 Secunderabad

### **NOTES:**

- 1. A MEMBER ENTITLED TO ATTEND AND TO VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND SUCH A PROXY NEED NOT BE A MEMBER OF THE COMPANY.
- 2. PROXY(IES) IN ORDER TO BE EFFECTIVE MUST BE RECEIVED AT THE COMPANY'S REGISTERED OFFICE NOT LESS THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.
- 3. EXPLANATORY STATEMENT PURSUANT TO THE PROVISIONS OF SECTION 102 OF THE ACT IS ATTACHED HEREWITH



### **EXPLANATORY STATEMENT**

Pursuant to Section 102 of the Companies Act, 2013

### Item No. 4, 5 & 6:

The Board of Directors appointed Dr. Padmanabhuni Venkata Appaji (DIN: 02614167) and Dr. Jang Bahadur Gupta (DIN 07751205) as additional directors in independent category w.e.f. March 20, 2017 and Dr. Gonuguntla Kathyayani as additional director in independent category w.e.f. May 19, 2017 subject to necessary compliances.

The said directors were appointed for a period of 5 years subject to the approval of the members in the ensuing annual general meeting of the Company.

The Company has received requests in writing from members of the company proposing their appointment as Directors of the Company in accordance with the provisions of Section 160 of the Companies Act, 2013. The Board feels their presence on the Board is desirable and would be beneficial to the Company and hence the Board recommends their appointment as Directors of the Company in the independent category.

Except the proposed appointees, none of the Directors, KMP or their relatives are interested in these resolutions.

By order of the Board for VANTA BIOSCIENCE LIMITED

M. Dopoul Raje

MULAKALA DOPESH RAJA

Managing Director DIN: 01176660

May 09, 2017 Secunderabad

### **DIRECTOR'S REPORT**

Dear Members

Your Directors have pleasure in presenting herewith the 1st Annual Report on the business of the Company together with the Financial Statements for the financial year ended March 31, 2017.

### **COMPANY AFFAIRS AND HIGHLIGHTS**

The Company was incorporated on April 29, 2016 with an objective of carrying business of providing research and development, full range of preclinical toxicology studies including in Vitro and In Vivo toxicity studies in the areas of pharmaceutical industry, agro chemical, food cosmetics and medical devices. There were no operations in the Company during the FY 2016-17.

The Company has acquired the "Vanta Bioscience" (a toxicology division) from Kemin Industries South Asia Private Limited including the facilities and has commenced commercial activities since April 2017.

All the pre-operative expenses have been capitalized as on the date of balance sheet.

### **DIVIDEND**

Your Directors do not recommend any dividend for the year.

### **TRANSFER TO RESERVES**

During the year, no amounts were transferred to general reserve.

### **DEPOSITS**

Your Company has not accepted any deposits falling within the preview of Section 73 of the Companies Act, 2013. During the year the Company has accepted unsecured loans from directors in terms of Rule 2(c)(viii) of Companies (Acceptance of Deposits) Rules, 2014 details of which are disclosed in financial statements.

## **DETAILS OF DIRECTORS OR KEY MANAGERIAL PERSONNEL**

Mr. Mohan Krishna Mohan Mulakala (DIN: 01448535) and Mr. Dopesh Raja Mulakala (DIN: 01176660) were the first directors of the Company.

In accordance with the provisions of Section 152 of the Companies Act, 2013, Mr. Mohan Krishna Mulakala (DIN: 01448535) is liable to retire by rotation, being eligible offers himself for reappointment.

During the year under review, Dr. Vyasmurti Madhavrao Shingatgeri (DIN: 07728757) was appointed as Additional Director w.e.f. 08.02.2017. The shareholders of the Company in their extra ordinary meeting held on 01.04.2015 have regularized him as a Director and appointed him as Whole Time Director of the Company.

Dr. Padmanabhuni Venkata Appaji (DIN 02614167) and Dr. Jang Bahadur Gupta (DIN: 07751205) were appointed as Additional Directors in Independent Category w.e.f. 20.03.2017. Dr. Gonuguntla Kathyayani was appointed as additional director in independent category w.e.f. 19.05.2017. Their regularization as Director is being proposed in this Annual General Meeting of the Company.

Mr. Venkata Rao Sadhanala and Mr. Zoheb Sultan Ali Sayani were appointed as Chief Financial Officer and Company Secretary of the Company respectively w.e.f. 02.05.2017

The Independent Directors have submitted the declaration of independence, pursuant to Section 149(7) of the Companies Act, 2013 stating that they meet the criteria of independence as provided under sub-section (6) of Section 149 of the Act.

### **CONVERSION OF COMPANY INTO A PUBLIC LIMITED COMPANY**

The Board of Directors of the Company proposed changing the status of the Company to a public limited company. The same was approved by the shareholders in their meeting held on 13.02. 2017.

The same was confirmed by the Registrar of Companies, Andhra Pradesh and Telangana on 17.03.2017 and a fresh certificate of incorporation was issued in this regard.

### **STATUTORY AUDITORS**

M/s. K B S & Associates, Chartered Accountants (FRN: 011208S) were appointed as the first auditors of the Company to hold the office upto the conclusion of the  $1^{\rm st}$  annual general meeting.

The said auditors retire at the conclusion of this annual general meeting and being eligible have offered themselves for re-appointment. In this regard, the Company has received a certificate from the auditors to the effect that if they are re-appointed, it would be in accordance with the provisions of Section 141 of the Companies Act, 2013.

The Board proposes their re-appointment as the Statutory Auditors of the Company for a term of 5 years from the conclusion of the  $1^{\rm st}$  annual general meeting till the conclusion of the  $6^{\rm th}$  annual general meeting subject to ratification by members each year.

### **AUDITORS' REPORT**

The Auditors' Report does not contain any qualification. Notes to Accounts and Auditors remarks in their report are self-explanatory and do not call for any further comments.



### **RISK MANAGEMENT POLICY**

The Company has not developed or implemented any Risk Management Policy. It has identified that there no such elements of risk, which in the opinion of the Board may threaten the existence of the Company.

## **INTERNAL FINANCIAL CONTROLS**

The Company has adequate internal financial controls commensurate with the size of the business of the Company.

## **DIRECTORS RESPONSIBILITY STATEMENT**

Pursuant to Section 134 (5) of the Companies Act, 2013 Your Directors' confirm that:

- In preparation of annual accounts for the financial year ended March 31, 2017 the applicable Accounting Standards have been followed along with proper explanation relating to material departures;
- ii. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the financial year ended March 31, 2017 and of the profit and loss of the Company for the year;
- iii. The Directors have taken proper and sufficient care for their maintenance of adequate accounting records in accordance with the provisions of the Companies Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv. The Directors had prepared the annual accounts on a going concern basis; and
- v. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

## CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE OUTGO

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is enclosed herewith as **Annexure - I.** 

## EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return in Form MGT-9 is annexed herewith as **Annexure - II**.

### **OTHER DISCLOSURES:**

### **BOARD MEETINGS**

During the year under review ten board meetings were held on 30.04.2016, 02.05.2016, 01.07.2016, 16.07.2016, 19.10.2016, 08.02.2017, 07.03.2017, 16.03.2017, 20.03.2017 and 30.03.2017. All Directors of the Company attended all the Board Meetings.

### PARTICULARS OF EMPLOYEES

During the year under review, the provisions of Section 197(12) of the Companies Act, 2013 are not applicable to the Company.

## PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

During the year under review, the Company has not granted any loans, given guarantees or made investments covered under Section 186 of the Companies Act, 2013.

## RELATED PARTY TRANSACTIONS

During the year the Company received Unsecured Loan of Rs. 5,38,53,920/- from one of the Directors of the Company Mr. Mohan Krishna and Equity Shares were allotted from an amount of Rs. 5,38,00,000/- against the Unsecured loans as above, and balance of Rs. 53,920/- remains as unsecured loan as end of the Balance Sheet.

### **GENERAL**

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

- 1. Issue of equity shares with differential rights as to dividend, voting or otherwise.
- 2. Issue of shares (including sweat equity shares) to employees of the Company under any scheme.
- 3. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Company's operations in future.
- 4. No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year and date of report.
- 5. No change in the nature of business of the Company.
- 6. There have been no Companies, which have become/ceased Subsidiaries, Joint Ventures or Associate Companies during the year under review.



Your Directors further state that during the year under review, there were no cases filed/registered pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

### **ACKNOWLEDGEMENT**

Your Directors place on record their appreciation of the continued patronage extended to the Company by bankers, dealers, customers, suppliers, employees and shareholders. The trust reposed in your Company by its esteemed customers helped stabilized growth during the year review.

Your Company also acknowledges the support and guidance received from its Bankers, other government agencies during the year under review and look forward to continuing support.

for and on behalf of the Board

DOPESH RAJA MULAKALA

Mi Dopert Roje

Managing Director DIN: 01176660

MOHAN KRISHNA MULAKALA

Director

DIN: 01448535

May 09, 2017 Secunderabad

# STATEMENT PURSUANT TO SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 READ WITH RULE 8 OF THE COMPANIES (ACCOUNTS) RULES, 2014

### (A) Conservation of energy-

- (i) the steps taken or impact on conservation of energy: Nil
- (ii) the steps taken by the company for utilizing alternate sources of energy: Nil
- (iii) the capital investment on energy conservation equipments: Nil

### (B) Technology absorption-

- (i) the efforts made towards technology absorption: Nil
- (ii) the benefits derived like product improvement, cost reduction, product development or import substitution: Nil
- (iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-
  - (a) the details of technology imported:

Nil

(b) the year of import:

Nil

- (c) whether the technology been fully absorbed: Nil
- (d) if not fully absorbed, areas where absorption has not taken place, and the reasons

thereof:

Ni]

(iv) the expenditure incurred on Research and Development: Nil

### (C) Foreign exchange earnings and Outgo:

The Foreign Exchange earned in terms of actual inflows during the year: Nil

The Foreign Exchange outgo during the year in terms of actual outflows: Rs. 2,24,737/-

for and on behalf of the Board

DOPESH RAJA MULAKALA

M. Doperh Rage

Managing Director

DIN: 01176660

MOHAN KRISHNA MULAKALA

M. M. Levielus

Director

DIN: 01448535

## FORM NO. MGT 9 EXTRACT OF ANNUAL RETURN

as on the financial year ended on 31-03-2017

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

### I. REGISTRATIONANDOTHERDETAILS:

CIN	U74999TG2016PLC109280
Registration Date	29/04/2016
Name of the Company	VANTA BIOSCIENCE LIMITED
	(formerly known as Vanta Bioscience Private
	Limited)
Category/Sub-Category of the Company	Company limited by Shares/
	Indian Non-Government Company
Address of the Registered office and	No.02/G/308/G No.3/Ff/Sf/1-20-248 Umajay
contact details	Complex Rasoolpura Secunderabad 500003
	Contact:: Tel: +91 40 6657 5454;
	Fax: +91 40 2790 8708
Whether listed company	-No-
Name, Address and Contact details of	-N.A
Registrar and Transfer Agent, if any	

### II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Business activities contributing 10 % or more of the total turnover of the company

S.No	Name and Description of	NIC Code of the	% to total turnover of
	main products/ services	Product/ service	the company
1	# "	*	-

### III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S.No	Name and	CIN/GLN	Holding/	% of shares	Applica
	Address of	·	Subsidiary/	held	ble
	The company		Associate		Section
		NIL			

### IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

### i) Category-wise Share Holding

Category of Shareholders		Shares held e year [As c		•		Shares held ar [As on 31			% Cha nge
	Dem at	Physical	Total	% of Total Share s	Dema t	Physical	Total	% of Tota I Shar es	duri ng the year
A. Promoters	2								
(1) Indian									
a) Individual/ HUF	<b>=</b>	20,000	20,000	100	(4)	36,46,000	36,46,000	100	



b) Central Govt	*	-	4	<u></u>	15	=	2	31	(8)
c) State Govt(s)	-		5	37	(e)		-	-	(48)
d) Bodies Corp.	e :	120		=	*	-	-	-	<b>∌</b> ?
e) Banks / FI	*	=/	-	*	-	5€	Tie .	=	2.
f) Any other	-	2.		-	-	3.5	>=	-	-
Sub Total (A) (1)		20,000	20,000	100	-	36,46,000	36,46,000	100	-
(2) Foreign									
a) NRI Individuals	-=!	2	~	9	-	-	e#X.	5 32	=
b) Other Individuals	= -	> <del>.</del>	=	5±3 94	-	₩	≤/	12.	16
c) Bodies Corp.	3.	12	<b>35</b> .0	•	*	*)	90	-	Væ.
d) Banks / FI	*	i=:	<b>a</b> . 1	Ψ'	Ě	3	=	<b>.</b>	
e) Any other	7		-	æ?	16	8	=	940	a:
Sub Total (A) (2)	-		=	**	\=	=	3	<b>3</b> .	(3)
Total (A)	-	20,000	20,000	100	-	36,46,000	36,46,000	100	-
B. Public Shareholding							±_		
1. Institutions									
a) Mutual Funds	•	; <del>@</del> ? ———	=	-	<=:	=	2	3	Ĭ.
b) Banks / FI		3)	7	=	*	=	I.S.	-	9
c) Central Govt	3.5	31	-	# 31	i=:	-	12	2	9
d) State Govt(s)	8	5	IIE			(#	æ	*	æk
e) Venture Capital Funds	-	2	120	-	¥	(2)	æ	=	=1
f) Insurance Companies	-	4	=	=	<i>≅</i> //	-	20.	ž	3.
g) FIIs	.=.	a III	=	: ==	39).	-	=		=
h) Foreign Venture Capital Funds	e.	-	•	72	ær	<u> </u>	¥.	.0	•
i) Others (specify)	•	200	*:	74	-	24	-	Œ	
Sub-total (B)(1):-	æ(	樓	150	· ·	-	•	*	(#)	-
2. Non- Institutions					1/-				
a) Bodies Corp.				->					
SEC-BAD	M								

0

-

i) Indian	ar .	==	÷	(4)	≀ë.	=	-	-	) <del>*</del> ):
ii) Overseas	-	ev.	=		. <del></del>	=	-	-	3;
b) Individuals									
i) Individual shareholders holding nominal share capital uptoRs. 1 lakh	3	8	8	*	œ.	ē	4	Я	<b>3</b> 7
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh			ı.	K	æ	12	. •	1	
c) Others (specify)	*	-		*	-	)3 <b>9</b> 2	796	=	*
Non Resident Indians	.6	=	4,5	-	-	,œ.		184	3
Overseas Corporate Bodies	)5	ä	16	ä	E#4	<u>.</u>	(#)	¥	5
Foreign Nationals	÷=	=	~=	=	<b>35</b>		*	8	=
Clearing Members	7 <b>%</b>	#	(=	-	32	:#:	(B)		-
Trusts		3	ίĒ		÷	· · · · · · · · · · · · · · · · · · ·	192	32	=:
Foreign Bodies - D R		×	(#	-	~	5 <b>7</b> 1	. <del></del>		2/
Sub-total (B)(2):-		*	36	•		2	12	#	97
Total Public (B)	>••	*	:: <del>*</del>	*	*	œ	5 <del>71</del> 1 41	*	3.)
C. Shares held by Custodian for GDRs & ADRs					74	2	:-	=	=3
Grand Total (A+B+C)	725	20,000	20,000	100	18:	36,46,000	36,46,000	100	-



## (ii) Shareholding of Promoters

S. No	Shareholder's Name		reholding a nning of th		Shareholo	Shareholding at the end of the year		
1)		No. of Shares	% of total Shares of the compan y	% of Shares Pledged / encumbe red to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumb ered to total shares	% change in share holding during the year
1)	-500 shares sold on 08.02.2017 -Allotment of 30,00,000 equity shares on 16.07.2016 -Allotment of 4,76,000 equity shares on 30.03.2017	10,000	29		32,55,550	55.00		23.00
2)	Dopesh Raja Mulakala -Allotment of 20,000 equity shares on 30.03.2017	10,000	50.00		30,000	0.82	30	(49.18)
3)	Mulakala Sujana Sheela - Shares acquired on 08.02.2017	) e.	) <del>*</del>	æ	100	0.00		0.00
4)	Dr. Simhadri Soumya - Shares acquired on 08.02.2017	æ	* (#	*	100	0.00	T.	0.00
5)	Chintapatla Karishma -Shares acquired on 08.02.2017 - Allotment of 50,000 equity shares on 30.03.2017	V2	190	-	50,100	1.37	=	1.37
6)	Chintapatla Shravan -Shares acquired on 08.02.2017	æ	æ		100	0.00	Ħ	0.00
7)	Mulakala Sajan Kiran -Shares acquired on 08.02.2017	-	×	-	100	0.00	#	0.00
8)		i.e	(er	*	80,000	2.19	#	2.19
	TOTAL	20,000	100	-	36,46,000	100	-	-

## (iii) Change in Promoters' Shareholding:

S.No			at the beginning ne year		Shareholding g the year
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	20,000	100	20,000	100
	Changes - 500 Shares transferred	20,000	0.55	20,000	100
	amongst promoter group on 08.02.2017 - Allotment of 30,00,000 equity	30,20,000	82.83	30,20,000	100
	shares on 16.07.2016 - Allotment of 6,26,000 equity shares on 30.03.2017	36,46,000	100	36,46,000	100
	At the End of the year	36,46,000	100	36,46,000	100

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs): All the shares are held by the promoter and directors of the Company

(v) Shareholding of Directors and Key Managerial Personnel:

S.	For each of the Director LVAC		lding at the g of the year	Sharehold	nulative ing during the vear
No	For each of the Directors and KMP	No. of Shares	% of total Shares of the	No. of Shares	% of total Shares of the
		-	company	oxiu200	company
1	Mohan Krishna Mulakala	10,000	50.00	34,86,000	95.61
2	Dopesh Raja Mulakala	10,000	50.00	30,000	0.82
	TOTAL	20,000	100	35,16,000	96.43



iii) Interest accrued but not due				295
Total (i + ii + iii)	572		400	
Net Change in Indebtedness during the financial year	7,50,00,000	53920	2021	7,50,53,920
Net Change	7,50,00,000	53,920	( <del>40</del> )	7,50,53,920
Indebtedness at the end of the financial year i) Principal Amount ii) Interest due but not paid	7,50,00,000	53,920		7,50,53,920
iii) Interest accrued but not due  Total (i+ii+iii)	7,50,00,000	53,920	<del>P</del> Å	7,50,53,920

# VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

S.No	Particulars of Remuneration	5		Total Amount
	Gross salary	-	-	€
1.	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	5 <b>=</b> 0	5	
2.	Stock Option		ļi	
3.	Sweat Equity	-	ļ — -	
4.	Commission - as % of profit - others, specify	•	-	
5.	Others, please specify	<u> </u>	•	
J.	Total (A)			
	Ceiling as per the Act		N.A.	

## B. Remuneration to other directors:

.No	Particulars of Remuneration	Name of Directors	Total Amount
11.	Independent Directors  • Fee for attending board / committee meetings  • Commission  • Others, please specify		•
2.	Total (1)	, ×	
	Other Non-Executive Directors		4

### B. Remuneration to other directors:

.No	Particulars of Remuneration	Name of Directors	Total Amount
1.	Independent Directors		-
: 4	Fee for attending board / committee		
	meetings		
	Commission		
	Others, please specify		
2.	Total (1)		-
	Other Non-Executive Directors		-
	Fee for attending board / committee		
	meetings		
	Commission		
	Others, please specify(Salary)		
	Total (2)	2	_
	Total (B)=(1+2)		-
	Total Managerial Remuneration	-	
	Overall Ceiling as per the Act	N.A.	-

C. Remuneration to KMP Other Than MD/Manager/WTD

S.No	Particulars of Remuneration	KMP	Total
			Amount
	Gross salary	2 <del>011</del>	
	(a) Salary as per provisions		
1.	contained in section 17(1) of		
	the Income-tax Act, 1961		
	(b) Value of perquisites u/s		
	17(2) Income-tax Act, 1961		
	(c) Profits in lieu of salary		
	under section 17(3) Income-		
	tax Act, 1961		
2.	Stock Option	¥1.0	-
3.	Sweat Equity	<u>-</u>	-
4.	Commission	-	-
	- as % of profit		
	- others, specify		
5.	Others, please specify	-	
	Total (A)	-	
	Ceiling as per the Act	N.A.	



## VII. PENALTIES / PUNISHMENT / COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD/ NCLT/ COURT]	Appeal made, if any (give Details)
Penalty		-	-		-
Punishment	-	-	-		-
Compounding		<u>-</u>	-	<u>-</u>	
	OTHER OFFICERS	IN DEFAULT			
Penalty	-	-	<u>-</u>		<u> </u>
Punishment		<u>-</u>		-	<u> </u>
Compounding	_	_	-	-	•

### for and on behalf of the Board

DOPESH RAJA MULAKALA

Managing Director

DIN: 01176660

MOHAN KRISHNA MULAKALA

Director

DIN: 01448535

May 09, 2017

## KBS & ASSOCIATES

## **Chartered Accountants**

### INDEPENDENT AUDITORS' REPORT

To
The Members of
M/s VANTA BIOSCIENCE LIMITED

### Report on the Financial Statements

1) We have audited the accompanying financial statements of M/s VANTA BIOSCIENCE LIMITED ("the Company"), which comprise the Balance Sheet as at March 31, 2017 and Cash Flow Statement for the year ended and a summary of significant accounting policies and other explanatory information.

### Management's Responsibility for the Financial Statements

2) The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### Auditors' Responsibility

3) Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under Section 143 (10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**

- 4) In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:
  - (a) In the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2017; and
  - (b) In the case of the Cash Flow Statement, of the cash flows for the year ended on that date

### Report on Other Legal and Regulatory Requirements

5) i. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we hereby attach an annexure on the Clauses of Paragraphs 3 and 4 of the said Order.

### ii. As required by Section 143 (3) of the Act, we report that:

- a. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b. In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
- c. The Balance Sheet and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d. In our opinion, the Balance Sheet and the Cash Flow Statement comply with the Accounting Standards referred to in Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors as on March 31, 2017, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2017, from being appointed as a director in terms of Section 164 (2) of the Act.
- f. With respect to the adequacy of internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in Annexure B
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us.

- i) The Company has disclosed the impact of pending litigations on its financial statements.
- ii) The company did not have any long-term contracts including derivative contracts for which there were any material foreseeable tosses.
- iii) There were no amounts which were required to be transferred to the investor Education and Protection Fund by the Company.
- iv) The company had provided requisite disclosures in its financial statements as to holdings as well as dealings in Specified Bank Notes during the period from 8<sup>th</sup> November, 2016 to 30<sup>th</sup> December, 2016 and these disclosures are in accordance with the books of accounts maintained by the company.

For KBS & ASSOCIATES

**Chartered Accountants** 

Reg. No. 011208S

K. KESAVA REDDY

Partner

M. No. 025317

Hyderabad, 9th May, 2017

### ANNEXURE TO AUDITORS' REPORT

The Annexure referred to in Para 5 (i) under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date, to the members of M/s Vanta Bioscience Limited, Secunderabad, for the year ended March 31, 2017.

- (i) a) The company has maintained proper records showing full particulars including quantitative details and situation of its Fixed Assets.
  - b) As explained to us, the management has physically verified the fixed assets during the year and there is a regular program which in our opinion is reasonable having regard to the size of the company and the nature of its assets. No material discrepancies with respect to book records were noticed on such verification.
  - c) The company is having title deeds of the immovable properties held by the company.
- (ii) a) In our opinion, as per information provided and explanations given to us that the nature of business of the company as such that the company do not have any inventory during the year under review.
- a) According to the information and explanation given to us during the year the Company has not granted any loans, secured or unsecured, to companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013.
  - b) In view of our comment in Paragraph (a) above, Clause (iii) (b) and (c) of paragraph 3 of the aforesaid Order are not applicable to the Company.
- iv) In our opinion and according to the information and explanations given to us that the company has not granted any loans, made investment and given guarantee and hence the provisions of Sections 185 and 186 of the Companies Act, 2013 are not applicable to the company.
- v) The company has not accepted any deposits from the public. Hence, the provisions of Section 73 and 76 or any other relevant provisions of the Companies Act, 2013, and the rules framed there under, do not apply to this Company.
- vi) We are informed that the Central Government has not prescribed the maintenance of cost records for the company u/s 148 of the Companies Act, 2013
- vii) a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales-tax, excise duty, customs duty, cess and other material statutory dues as applicable, with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, Income tax, sales tax, service tax, duty of customs, duty of excise, value added

- tax, cess and other material statutory dues were in arrears as at 31<sup>st</sup> March, 2017 for a period of more than six months from the date they became payable.
- b) According to the information and explanations given to us and the records of the company examined by us, there are no dues of sales tax, wealth tax, customs duty, service tax, cess which have not been deposited on account of any dispute.
- viii) In our opinion and according to the information provided and explanations given to us that, the company has not defaulted in repayment of loans or borrowing from banks or financial institutions.
- ix) In our opinion and according to the information and explanations given to us that the company has not raised any money from Initial Public Offer, Further Public Offer and Term Loans during the year under review.
- x) As per our audit procedures performed during the year under review, we observed that no fraud by the company or any fraud on the company by officers or employees of the company has been noticed or reported during the year.
- As per information provided and explanations given to us that the company has not paid any managerial remuneration to the Directors of the company during the year under review.
- xii) According to the information and explanations given to us, the company is not a Nidhi Company and hence the compliance with the Net Owned Funds to Deposits is not applicable to the company.
- xiii) In our opinion, as per information provided and explanations given to us, the company has not entered into any related party transactions during the year.
- xiv) During the year the company has made preferential allotment of 30,00,000 equity shares at par on preferential basis. The company has not made private placement of shares or fully or partly convertible debentures during the year under review.
- xv) The company has not entered into any noncash transactions with directors or persons connected with the company.
- xvi) The company is not required to be registered under Section 45-IA of the Reserved Bank of India Act, 1934.

For KBS & ASSOCIATES

**Chartered Accountants** 

Reg. No. 011208S

K. KESAVA REDDY

Partner

M. No. 025317

Hyderabad, 9th May, 2017

Annexure - B" to the Independent Auditor's Report of even date on the Financial Statements of M/s Vanta Bioscience Limited

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of M/s Vanta Bioscience Limited ("the Company") as of March 31, 2017 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

### Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

### Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls and, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### Meaning of Internal Financial Controls over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

### Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, and to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For K B S & ASSOCIATES

Chartered Accountants

Firm Reg. No. 011208S

K. KESAVA REDDY

Partner

M. No. 025317

Hyderabad, 9th May, 2017

### 1. NOTES FORMING PART OF FINANCIAL STATEMENTS:

M/s Vanta Bioscience Private Limited ('the Company') was incorporated on 29<sup>th</sup> April 2016 as a Private Limited Company with its registered office at Hyderabad, Telangana. After that the Company was converted as Vanta Bioscience Limited as Public Limited company as on 17<sup>th</sup> March, 2017. The Company is engaged in the business of Research and Development, Pre-clinical Testing and Toxicology Studies and Services and other R&D related services.

### 2. SIGNIFICANT ACCOUNTING POLICIES:

### I. Method of Accounting:

The financial statements are prepared under historical cost convention, in accordance with the accounting principles generally accepted in India having due regard to fundamental accounting assumption of going concern, consistency and accrual. The Company follows accrual method of accounting.

### II. Revenue Recognition:

The company has not carried on any operations during the year and there is no Revenue to be recognized.

#### Fixed Assets:

Fixed Assets are stated at cost of acquisition. Cost comprises of the purchase price and other attributable expenses including cost of borrowing till the date of capitalization of the fixed asset.

### III. Depreciation:

The Company has not provided depreciation on fixed assets of the company as the company has not carried any commercial activity during the year under audit.

#### IV. Taxes on Income:

Current Tax not provided as there is no taxable income during the year.

Deferred Tax: Deferred Tax is not recognized as there are no timing difference being the difference between taxable incomes and accounting income that originate in one period and are capable of being reversed in the subsequent periods, subject to the consideration of prudence.



### **VANTA BIOSCIENCE LIMITED**

No. 02/G/308/G No.3/FF/SF/ 1-20-248, Umajay Complex, Rasoolpura, Secunderabad - 500003.

### **BALANCE SHEET AS AT 31.03.2017**

	Note No.	As at 31-03-2017
I EQUITY & LIABILITIES :	NO.	31-03-2017
1. Shareholder's Funds :		0.04.00.000
a) Share Capital	3	3,64,60,000
b) Reserves	4	2,50,40,000
2. Non-current Liabilities :		
Long Term Borrowings	5	7,50,00,000
3. Current Liabilities :		
a) Short Term Borrowings	6	53,920
b) Other Current Liabilities	7	9,05,203
	TOTAL	13,74,59,123
II ASSETS:		
1. Non-current Assets :		
(a) Fixed Assets :		
Tangible Assets	8	12,94,60,857
(b) Long Term Loans and Advances	9	27,48,070
2. Current Assets :		
(a) Cash and cash equivalents	10	44,45,166
(b) Other Current Assets	11	2,31,510
3. Miscellaneous Expenditure :	12	5,73,520
(To the extent not written off or adjusted)		
	TOTAL	13,74,59,123

The accompanying notes are an integral part of the Financial Statements.

As per our attached Report of even date

For K B S & ASSOCIATES

**Chartered Accountants** 

Fifm Regn. No. 011208S

K. KESAVA REDDY

Partner

M.No. 025317

ZOHEB SAYANI Company Secretary For and on behalf of the Board

M. DOPESH RAJA

Managing Director

DIN: 01176660

M. MOHAN KRISHNA

Director

DIN:01448535

VENKAT RAO SADHANALA

Chief Financial Officer

May 09, 2017 Secunderabad

## VANTA BIOSCIENCE LIMITED CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2017

CASH FLOW STATEMENT FOR THE YEAR ENDED 3131 MARCH	2017	(Figures in ₹ )
PARTICULARS	Current Year 31.03.2017	Previous Year 31.03.2016
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before Exceptional, Extraordinary items and Tax	( <b>●</b> );	\ <b>*</b> ;
Adjustment for :		8
Depreciation	•	3.50
Interest Earned	3	₹ <b>=</b> 1
Interest Paid	: <del>=</del> <	4,50
sub-total	•	¥
Operating Profit Before Working Capital Changes		5.
Adjustment for :		
Increase/(Decrease) in Other Payables	9,05,203	=
(Increase)/Decrease Loans, Advances and Others	(35,53,100)	ŝ
sub-total	(26,47,897)	·
Cash Generated From Operations	(26,47,897)	•
Direct Taxes Paid	196	×
Net Cash flow from Operating Activities (A)	(26,47,897)	· ₹
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(12,94,60,857)	п =
Net Cash flow from Investing Activities (B)	(12,94,60,857)	3
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) Equity Share Capital	3,64,60,000	9
Increase/(Decrease) Share Premium	2,50,40,000	1#0
Increase/(Decrease) in Unsecured Loans	53,920	3
Increase/(Decrease) in Term Loan	7,50,00,000	
Net Cash flow from Financing Activitie (C)	13,65,53,920	w.
D. Net Increase/(Decrease) in Cash and Cash Equivalents ( A+B	44,45,166	5,€5
Opening Balance of Cash and Cash Equivalents	4.	72
Closing Balance of Cash and Cash Equivalents	44,45,166	199

Note: The Cash Flow Statement has been prepared under the indirect method as set out in the Accounting AS-3 Cash Flow Statements issued by the Institute of Chartered Accountants of India.

As per our attached Report of even date

For K B S & ASSOCIATES

Chartered Accountants

Firm Regn. No. 011208S

K. KESAVA REDDY

Partner

M.No. 025317

May 09, 2017 Secunderabad ZOHEB SAYANI Company Secretary For and on behalf of the Board

M. DOPESH RAJA

Managing Director

DIN: 01176660

M. MOHAN KRISHNA

Director

DIN:01448535

VENKAT RAO SADHANALA

Chief Financial Officer

### **VANTA BIOSCIENCE LIMITED:**

As at 31-03-2017

3. Share Capital:
Authorised:

45,00,000 Equity Shares of Rs.10/-each

Issued, Subscribed and Paid up:

36,46,000 Equity Shares of 10/- each

3,64,60,000

### 3.1 The details of shareholders holding more than 5% of shares.

Name of the Shareholder	No. of Shares held	% of Holding
M. Mohan Krishna	34,85,500	95.60%
3.2 The reconciliation of the number of shares outsta	anding is set out below :	Equity

Shares outstanding at the beginning of the year

Shares Issued during the year

Shares redeemed/bought back during the year

Shares outstanding at the end of the year

36,46,000

### 4. Reserves

Share Premium 2,50,40,000

2,50,40,000

#### 5. Long Term Borrowings:

Term Loan From SBI

7,50,00,000

7,50,00,000

Limit

No. of Instalments

Rate of Interest

Term Loan

14,00,00,000 27 Qtrs

3.75 % above 1 Year MCLR, effective rate being 11.75%pa

- a) Repayment of first instalment starts from 4th quarter of the year 2017-18
- b) The loan will be repaid upto the year 2024 2025
- c) Primary Security: The term loan secured by way of hypothecation of Building, Plant & Machinery and other Fixed Assets of the Company situated at Plot No. k2, 11th Cross, SIPCOT Industrial Complex, Gummidipudi, Tamilnadu 601201.
- d) Collateral Security: Commercial Property at Module A1,2,3, Quarter 3, 5th Floor, Cyber Towers, Madhapur, Serilingampally, R R Dist, Telangana 500050, owned by one of the Directors of the Company and personaguarantee of Directors of the company.

### 6. Short Term Borrowings:

Unsecured Loans from Directors

53,920

53,920

### 7. Other Current Liabilities :

(a) Outstanding Interest on Term Loan	1,55,137
(a) Creditors for Expenses	1,32,200
(b) Creditors for Capital Goods	6,09,746
(c) TDS Payables	8,120

9,05,203

#### 8. Fixed Assets:

		Gross Block			Net Block
Name of the Asset	Acquired during the year	Deletions	As on 31-03-2017	For the year	As on 31-03-2017
			_		DI
Land - Leasehold Rights	1,17,50,795		1,17,50,795	-	1,17,50,795
Buildings	5,62,98,858		5,62,98,858	-	5,62,98,858
Plant & Machinery	2,63,32,187	-	2,63,32,187	-	2,63,32,187
Electrical Equipment	47,01,690	-	47,01,690	-	47,01,690
Lab Equipment	91,43,717	-	91,43,717	-	91,43,717
Office Equipment	1,30,94,459	-	1,30,94,459	-	1,30,94,459
Furniture and Fixtures	20,59,024	-	20,59,024	-	20,59,024
Computers	8,22,271	-	8,22,271	-	8,22,271
D. G. Set	39,54,911	-	39,54,911	-	39,54,911
Misc. Fixed Assets	13,02,945	-	13,02,945	-	13,02,945
Total	12,94,60,857		12,94,60,857	-	12,94,60,857

### 9. Long Term Loans and Advances::

Electricity Deposit 27,48,070

27,48,070

### 10. Cash and Cash equivalents:

a) Balances with Scheduled Banks 41,81,150

b) Cash on Hand 2,64,016

44,45,166

### 11. Other Current Assets:

Prepaid Expenses 2,31,510

2,31,510

### 12. Miscellaneous Expenditure :

Preliminary Expenses to the extent not written off

5,73,520

### NOTES FORMING PART OF ACCOUNTS:

- i. The management has stated that there are no Micro, Small and Medium Business Enterprises to whom the company owes dues which are outstanding more than 45 days as at 31<sup>st</sup> March, 2017. The information as required to be disclosed under the Micro, Small and Medium Enterprises Act, 2006 has been determined to the extent of such parties have been identified on the basis of the information available with the company.
- ii. In the opinion of the management, current assets, loans and advances have a value and realization will be equal to the amount at which they are stated in the balance sheet.
- iii. In the absence of confirmation by some of the sundry creditors balances in respect of the same are as per the books only. The balances of creditors subject to reconciliation and adjustment thereon having an impact of revenue nature, if any, will be made in the year in which the same are finally settled.
- Payments to Auditors for the year comprises as follows:
  Fees for Statutory Audit
  Service Tax

  Rs. 50,000/Rs. 7,500/-
- v. Segment Reporting: The Company is engaged in the business of Research and Development, Testing, Pre-clinical and Clinical Testing, Toxicology Studies, Contract Research. Accordingly, for reporting purposes all these services are treated as a single Business and Geographical Segment. The said treatment is in accordance with Accounting Standard 17, Segment Reporting.
- vi. Details of Specified Bank Notes held and transacted during the period from 8<sup>th</sup> November, 2016 to 30<sup>th</sup> December, 2016 as follows:

	SBNs	Other Denomination Notes	Total
Closing cash in hand as on 08/11/2016	20,000	1,99,284	2,19,284
(+)Permitted Receipts		24,000	24,000
(-)Permitted Payments			
(-)Amount deposited in Banks	20,000		20,000
Closing cash on Hand as on 30-12- 2016	NIL	2,23,284	2,23,284



#### vi. Earnings Per Share:

In accordance with Accounting Standards – 20 with respect to Earnings per Share (EPS) issued by the Institute of Chartered Accountants of India (ICAI), the Basic and Diluted Earnings Per Share (EPS) has been calculated as under:

	₹	₹
Net Profit after Tax	Nil	NA
Equity Shares (No's)	36,46,000	NA
Basic and Diluted Earnings Per Share	Nil	NA
Face Value per Equity Share	Nil	NA

vii. C I F Value of Imports (Rs.)

viii. Expenditure on Foreign Currency (Rs.)

2,24,737

Earnings on Foreign Currency ix. (Rs.)

Providing Previous year's figures is not necessary as this is the first year of X. incorporation of the company

xi. Paise have been rounded off to the nearest rupee.

As per our attached Report of even date.

For K B S & ASSOCIATES

Chartered Accountants Firm Reg. No. 011208S

K. KESAVA REDD

Partner

May 09, 2017

**Secunderabad** 

M. No. 025317

For and on behalf of the Board

M. DOPESH RAJA Managing Director

₹

DIN: 01176660

M. MOHAN KRISHNA

Director

DIN: 01448535

VENKAT RAO SADHANALA

S. venicate 20

Chief Financial Officer

**ZOHEB SAYANI** Company Secretary